Key terms

About COGT

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest COGT news

Feb 27 11:40pm ET Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Celldex (CLDX) and Laboratory (LH) Feb 27 7:30am ET Analysts Offer Insights on Healthcare Companies: Cigna (CI), Cogent Biosciences (COGT) and Canopy Growth (CGC) Feb 26 9:40am ET Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) Feb 26 9:24am ET Cogent Biosciences price target raised to $19 from $13 at H.C. Wainwright Feb 26 8:03am ET Cogent Biosciences expects cash to fund requirements into 2027 Feb 26 8:02am ET Cogent Biosciences reports Q4 EPS (63c), consensus (55c) Feb 26 6:37am ET Cogent Biosciences price target raised to $13 from $11 at Citi Feb 26 4:58am ET Cogent Biosciences downgraded to Neutral from Outperform at Baird Feb 26 4:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) Feb 23 8:40am ET Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX) Feb 23 8:31am ET Cogent Biosciences price target raised to $18 from $15 at Needham Feb 23 7:11am ET Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT) Feb 23 6:06am ET Buy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market Potential Feb 22 2:32pm ET Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial Feb 22 12:17am ET Buy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib’s Efficacy and Safety Feb 15 1:17am ET Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential Feb 14 6:52pm ET Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT) Feb 14 7:21am ET Cogent Biosciences announces oversubscribed $225M private placement Feb 14 7:20am ET Cogent Biosciences sells 17M shares at $7.50 in private placement Feb 12 5:25am ET Cogent Biosciences: A Balanced Buy Rating Ahead of Key Data Release Feb 08 5:07am ET Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects Feb 08 4:54am ET Cogent Biosciences initiated with a Buy at Citi Jan 09 8:08am ET Cogent Biosciences announces planned 2024 milestones Dec 15 6:28am ET Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial Dec 15 6:17am ET Cogent Biosciences price target lowered to $13 from $27 at H.C. Wainwright Dec 15 6:17am ET Cogent Biosciences price target lowered by $14 at H.C. Wainwright, here’s why Dec 13 1:17am ET Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib Dec 11 12:56pm ET Wedbush downgrades Cogent Biosciences to Neutral, cuts price target to $5 Dec 11 12:52pm ET Cogent Biosciences just downgraded at Wedbush, here’s why Dec 11 10:45am ET Needham biotechnology analyst to hold an analyst/industry conference call Dec 11 9:41am ET Cogent Biosciences trading resumes

No recent news articles are available for COGT

No recent press releases are available for COGT

COGT Financials

1-year income & revenue

Key terms

COGT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

COGT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms